Avalo Therapeutics, Inc. - COMMON STOCK (AVTX)

CUSIP: 05338F306

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class
Equity / COMMON STOCK
Shares outstanding
18,485,383
Total 13F shares
87,507
Share change
+64,537
Total reported value
$1,897,924
Price per share
$21.75
Number of holders
18
Value change
+$1,405,693
Number of buys
10
Number of sells
6

Quarterly Holders Quick Answers

What is CUSIP 05338F306?
CUSIP 05338F306 identifies AVTX - Avalo Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) as of Q1 2024

As of 31 Mar 2024, Avalo Therapeutics, Inc. - COMMON STOCK (AVTX) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 87,507 shares. The largest 10 holders included Ikarian Capital, LLC, Sio Capital Management, LLC, Affinity Asset Advisors, LLC, UBS Group AG, ADAR1 Capital Management, LLC, NATIXIS, BlackRock Inc., Tower Research Capital LLC (TRC), Banque Cantonale Vaudoise, and Royal Bank of Canada. This page lists 18 institutional shareholders reporting positions in this security for the Q1 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.